6762.T (6762.T)
Quantitative Summary
DeterministicStrong operational fundamentals (Piotroski 8/9) with Altman Z of 2.9.
Generated deterministically from quant metrics and financial statements. Not a recommendation.
Algorithmic Teardown
AI-GeneratedThe fundamental economics reveal a company generating modest capital efficiency, with an ROIC of 8.1% barely exceeding its WACC by only 0.5%, suggesting limited value creation from deployed equity relative to the cost of capital. Despite this narrow spread, financial stability appears robust given a Piotroski F-Score of 8/9 and an Altman Z-Score of 2.9, indicating strong balance sheet health without excessive leverage risks. The DuPont decomposition highlights that returns are primarily driven by operational efficiency rather than margin expansion or leverage; while net margins sit at 7.6% with gross margins at 31.2%, revenue growth remains subdued at 4.8% year-over-year, constraining the top-line momentum necessary to widen the ROIC-WACC gap in future periods.
Valuation metrics present a mixed picture where the current P/E of 21.6x sits significantly above implied fair value derived from DCF analysis, which points to $2051 per share. This discrepancy suggests the market is pricing in growth assumptions that may not be fully supported by the observed 4.8% revenue trajectory or the marginal capital efficiency gains currently being realized. The premium valuation implies high expectations for future margin expansion or acceleration in turnover ratios that have yet to materialize in recent financial statements, creating a potential divergence between current multiples and intrinsic value estimates based on discounted cash flow modeling.
No specific risk factor deltas, insider activity data, or Fama-French alpha metrics were provided to further contextualize the investment case beyond these fundamental and valuation observations.
Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.
DCF Sandbox
InteractiveSensitivity Matrix
| TG ↓ / WACC → | 6% | 7.7% | 9.7% |
|---|---|---|---|
| 2% | $2428 | $1782 | $1374 |
| 3% | $3056 | $2051 | $1504 |
| 4% | $4313 | $2468 | $1679 |
Center = base case. Green = >10% upside, Red = >10% downside vs —.
Pre-computed DCF: WACC=7.7%, terminal growth 3%. Fair value $2051 (+0.0%). Not investment advice.
Price Chart with Moving Averages
Quant Health Deep Dive
Profitability & Value Creation
✅ Conservative payout — room for dividend increases.
Balance Sheet Health
Earnings Surprise History
EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.
Underwater (Drawdown from Peak)
How far below the all-time high the price has been over time. Deeper = more pain for holders.
Rolling 60-Day Beta vs S&P 500 (VOO)
How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.
Fundamentals
6762.T Capital Efficiency
How efficiently does 6762.T convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.
6762.T converts 49% of its EBITDA into free cash flow, a healthy conversion rate indicating efficient capital management — the business generates substantial cash after reinvestment. The 51% reinvestment rate signals aggressive capacity expansion. The positive ROIC-WACC spread of 0.5% confirms that reinvested capital creates shareholder value.
Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.
Compare 6762.T to Peers
Quant metrics computed deterministically from financial statements and price data. Updated: N/A.
SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.